AstraZeneca plc (AZN) PT Set at GBX 7,000 by Societe Generale
AstraZeneca plc (LON:AZN) has been given a GBX 7,000 ($93.23) price target by equities research analysts at Societe Generale in a research report issued to clients and investors on Thursday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Societe Generale’s price objective points to a potential upside of 43.84% from the company’s current price.
Other analysts have also recently issued research reports about the company. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 4,800 ($63.93) target price on shares of AstraZeneca plc in a report on Thursday, July 21st. Jefferies Group boosted their target price on AstraZeneca plc from GBX 4,600 ($61.27) to GBX 4,800 ($63.93) and gave the stock a “hold” rating in a report on Thursday, July 14th. BNP Paribas reiterated an “outperform” rating and set a GBX 5,000 ($66.60) target price on shares of AstraZeneca plc in a report on Wednesday, June 15th. HSBC set a GBX 4,815 ($64.13) target price on AstraZeneca plc and gave the stock a “neutral” rating in a report on Tuesday, August 2nd. Finally, Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of GBX 4,919.39 ($65.52).
AstraZeneca plc (LON:AZN) traded down 0.22% on Thursday, hitting GBX 4866.50. 2,038,270 shares of the stock traded hands. The firm’s 50-day moving average price is GBX 4,967.17 and its 200-day moving average price is GBX 4,294.47. The stock’s market cap is GBX 61560.43 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/08/astrazeneca-plc-azn-pt-set-at-gbx-7000-by-societe-generale.html
The company also recently announced a dividend, which will be paid on Monday, September 12th. Investors of record on Thursday, August 11th will be paid a dividend of GBX 68.70 ($0.92) per share. The ex-dividend date is Thursday, August 11th. This represents a yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related companies with MarketBeat.com’s FREE daily email newsletter.